{
  "lastUpdated": "2026-02-23",
  "categories": [
    {
      "id": "vaccines",
      "name": "Vaccines & Immunization",
      "icon": "ðŸ’‰",
      "description": "Next-generation vaccine platforms and novel immunization strategies"
    },
    {
      "id": "oncology",
      "name": "Oncology & Cancer Treatment",
      "icon": "ðŸŽ—ï¸",
      "description": "Breakthrough cancer therapies including CAR-T, checkpoint inhibitors, and targeted treatments"
    },
    {
      "id": "neurology",
      "name": "Neurology & Brain Health",
      "icon": "ðŸ§ ",
      "description": "Treatments for Alzheimer's, Parkinson's, and other neurological conditions"
    },
    {
      "id": "rare-diseases",
      "name": "Rare & Orphan Diseases",
      "icon": "ðŸ§¬",
      "description": "Gene therapies and treatments for rare genetic conditions"
    },
    {
      "id": "infectious",
      "name": "Infectious Diseases",
      "icon": "ðŸ¦ ",
      "description": "Antivirals, antibiotics, and treatments for emerging pathogens"
    }
  ],
  "companies": [
    {
      "id": "moderna",
      "name": "Moderna",
      "logo": "https://logo.clearbit.com/modernatx.com",
      "headquarters": "Cambridge, MA, USA",
      "founded": 2010,
      "focus": ["mRNA therapeutics", "Vaccines", "Oncology"],
      "marketCap": "$45.2B",
      "website": "https://www.modernatx.com",
      "trials": [
        {
          "id": "mrna-1283",
          "name": "mRNA-1283 Next-Gen COVID-19 Vaccine",
          "phase": "Phase 3",
          "status": "Active",
          "category": "vaccines",
          "indication": "COVID-19 Prevention (Omicron-specific)",
          "enrollment": 25000,
          "startDate": "2025-03",
          "estimatedCompletion": "2026-09",
          "description": "Next-generation mRNA vaccine targeting multiple Omicron subvariants with improved durability and broader protection.",
          "primaryEndpoints": ["Neutralizing antibody response", "Vaccine efficacy against symptomatic infection"],
          "latestUpdate": {
            "date": "2026-02-15",
            "summary": "Interim analysis shows 78% efficacy against symptomatic infection. Strong T-cell responses observed across age groups."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Jacqueline Miller",
              "role": "Senior VP, Infectious Disease Development",
              "mdrpediaSlug": null
            }
          ],
          "sites": 180,
          "countries": ["USA", "UK", "Germany", "Japan", "Brazil"]
        },
        {
          "id": "mrna-4157",
          "name": "mRNA-4157/V940 (Personalized Cancer Vaccine)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Melanoma (adjuvant treatment)",
          "enrollment": 1089,
          "startDate": "2023-07",
          "estimatedCompletion": "2029-12",
          "description": "Individualized neoantigen therapy in combination with Keytruda for high-risk melanoma patients post-surgery.",
          "primaryEndpoints": ["Recurrence-free survival", "Overall survival"],
          "latestUpdate": {
            "date": "2026-02-10",
            "summary": "Phase 2b results showed 44% reduction in recurrence/death risk vs Keytruda alone. FDA granted Breakthrough Therapy designation."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Jeffrey Weber",
              "role": "Deputy Director, Perlmutter Cancer Center, NYU",
              "mdrpediaSlug": null
            }
          ],
          "sites": 165,
          "countries": ["USA", "Australia", "UK", "Germany", "France"]
        },
        {
          "id": "mrna-3927",
          "name": "mRNA-3927 (Propionic Acidemia Gene Therapy)",
          "phase": "Phase 1/2",
          "status": "Active",
          "category": "rare-diseases",
          "indication": "Propionic Acidemia",
          "enrollment": 24,
          "startDate": "2024-01",
          "estimatedCompletion": "2027-06",
          "description": "mRNA therapy encoding PCCA and PCCB enzymes for this life-threatening metabolic disorder.",
          "primaryEndpoints": ["Safety", "Reduction in metabolic decompensation events"],
          "latestUpdate": {
            "date": "2026-01-28",
            "summary": "All 12 patients in dose-escalation phase showed reduced plasma biomarkers. No serious adverse events reported."
          },
          "leadInvestigators": [],
          "sites": 8,
          "countries": ["USA", "UK"]
        }
      ]
    },
    {
      "id": "pfizer",
      "name": "Pfizer",
      "logo": "https://logo.clearbit.com/pfizer.com",
      "headquarters": "New York, NY, USA",
      "founded": 1849,
      "focus": ["Vaccines", "Oncology", "Rare Diseases", "Immunology"],
      "marketCap": "$158.7B",
      "website": "https://www.pfizer.com",
      "trials": [
        {
          "id": "pf-07304814",
          "name": "PF-07304814 (Universal Coronavirus Vaccine)",
          "phase": "Phase 2",
          "status": "Active",
          "category": "vaccines",
          "indication": "Pan-coronavirus protection",
          "enrollment": 4500,
          "startDate": "2025-06",
          "estimatedCompletion": "2027-03",
          "description": "Novel vaccine targeting conserved regions of coronaviruses to provide broad protection against future variants and related viruses.",
          "primaryEndpoints": ["Cross-reactive antibody response", "T-cell immunity breadth"],
          "latestUpdate": {
            "date": "2026-02-18",
            "summary": "Phase 1 data demonstrated robust cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2 variants, and MERS-CoV."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Kathrin Jansen",
              "role": "Former Head of Vaccine R&D",
              "mdrpediaSlug": null
            }
          ],
          "sites": 95,
          "countries": ["USA", "Germany", "South Africa", "Singapore"]
        },
        {
          "id": "pf-06939926",
          "name": "Fordadistrogene Movaparvovec (DMD Gene Therapy)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "rare-diseases",
          "indication": "Duchenne Muscular Dystrophy",
          "enrollment": 99,
          "startDate": "2022-06",
          "estimatedCompletion": "2026-12",
          "description": "AAV-based gene therapy delivering micro-dystrophin for ambulatory boys with DMD aged 4-7.",
          "primaryEndpoints": ["North Star Ambulatory Assessment change", "Micro-dystrophin expression"],
          "latestUpdate": {
            "date": "2026-02-05",
            "summary": "52-week data shows significant improvement in muscle function. BLA submission expected Q3 2026."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Jerry Mendell",
              "role": "Director, Center for Gene Therapy, Nationwide Children's",
              "mdrpediaSlug": null
            }
          ],
          "sites": 35,
          "countries": ["USA", "UK", "Italy", "Spain"]
        },
        {
          "id": "sasanlimab",
          "name": "Sasanlimab (Anti-PD-1) + Elranatamab Combo",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Relapsed/Refractory Multiple Myeloma",
          "enrollment": 750,
          "startDate": "2024-09",
          "estimatedCompletion": "2028-06",
          "description": "Combination of subcutaneous PD-1 inhibitor with BCMA-CD3 bispecific antibody for heavily pretreated myeloma.",
          "primaryEndpoints": ["Progression-free survival", "Overall response rate"],
          "latestUpdate": {
            "date": "2026-01-30",
            "summary": "Early cohort shows 68% overall response rate with manageable safety profile. Enrollment ahead of schedule."
          },
          "leadInvestigators": [],
          "sites": 120,
          "countries": ["USA", "Japan", "Germany", "France", "Australia"]
        }
      ]
    },
    {
      "id": "biontech",
      "name": "BioNTech",
      "logo": "https://logo.clearbit.com/biontech.de",
      "headquarters": "Mainz, Germany",
      "founded": 2008,
      "focus": ["mRNA therapeutics", "Cancer immunotherapy", "Infectious diseases"],
      "marketCap": "$28.4B",
      "website": "https://www.biontech.de",
      "trials": [
        {
          "id": "bnt162b4",
          "name": "BNT162b4 (T-Cell Boosting COVID Vaccine)",
          "phase": "Phase 2",
          "status": "Active",
          "category": "vaccines",
          "indication": "COVID-19 (Enhanced T-cell response)",
          "enrollment": 1800,
          "startDate": "2025-08",
          "estimatedCompletion": "2026-11",
          "description": "Novel vaccine component designed to enhance T-cell immunity for longer-lasting protection regardless of variants.",
          "primaryEndpoints": ["T-cell response magnitude", "Duration of cellular immunity"],
          "latestUpdate": {
            "date": "2026-02-12",
            "summary": "Phase 1 showed 4-fold increase in virus-specific T-cells persisting at 6 months. Moving to expanded Phase 2."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Ugur Sahin",
              "role": "CEO & Co-founder, BioNTech",
              "mdrpediaSlug": null
            },
            {
              "name": "Dr. Ã–zlem TÃ¼reci",
              "role": "CMO & Co-founder, BioNTech",
              "mdrpediaSlug": null
            }
          ],
          "sites": 45,
          "countries": ["Germany", "USA", "UK"]
        },
        {
          "id": "bnt211",
          "name": "BNT211 (CAR-T + mRNA Vaccine for Solid Tumors)",
          "phase": "Phase 1/2",
          "status": "Active",
          "category": "oncology",
          "indication": "Claudin-6 positive solid tumors",
          "enrollment": 180,
          "startDate": "2023-03",
          "estimatedCompletion": "2027-09",
          "description": "First-in-class combination of CAR-T cells with mRNA vaccine boosting targeting Claudin-6 in ovarian, testicular, and lung cancers.",
          "primaryEndpoints": ["Overall response rate", "CAR-T cell persistence"],
          "latestUpdate": {
            "date": "2026-02-01",
            "summary": "59% objective response rate in evaluable patients. Complete responses seen in 3 ovarian cancer patients."
          },
          "leadInvestigators": [],
          "sites": 22,
          "countries": ["Germany", "USA", "Spain"]
        },
        {
          "id": "bnt141",
          "name": "BNT141 (mRNA Cancer Immunotherapy)",
          "phase": "Phase 1",
          "status": "Active",
          "category": "oncology",
          "indication": "CLDN18.2+ Gastric Cancer",
          "enrollment": 90,
          "startDate": "2025-01",
          "estimatedCompletion": "2027-06",
          "description": "Intravenously administered mRNA encoding a secreted antibody targeting Claudin 18.2.",
          "primaryEndpoints": ["Safety", "Antibody expression levels", "Tumor response"],
          "latestUpdate": {
            "date": "2026-01-15",
            "summary": "Dose escalation ongoing. Therapeutic antibody levels detected in all patients at higher dose levels."
          },
          "leadInvestigators": [],
          "sites": 15,
          "countries": ["Germany", "Spain", "USA"]
        }
      ]
    },
    {
      "id": "novartis",
      "name": "Novartis",
      "logo": "https://logo.clearbit.com/novartis.com",
      "headquarters": "Basel, Switzerland",
      "founded": 1996,
      "focus": ["Oncology", "Cardiovascular", "Immunology", "Neuroscience"],
      "marketCap": "$212.5B",
      "website": "https://www.novartis.com",
      "trials": [
        {
          "id": "kymriah-all",
          "name": "Kymriah (Tisagenlecleucel) in Pediatric ALL",
          "phase": "Phase 4 (Post-Marketing)",
          "status": "Active",
          "category": "oncology",
          "indication": "Pediatric B-cell ALL (Expanded Age Range)",
          "enrollment": 350,
          "startDate": "2024-06",
          "estimatedCompletion": "2028-12",
          "description": "Real-world study evaluating CAR-T therapy in broader pediatric population including infants.",
          "primaryEndpoints": ["Complete remission rate", "Event-free survival", "Long-term safety"],
          "latestUpdate": {
            "date": "2026-02-08",
            "summary": "92% complete remission rate maintained. FDA approved expanded indication down to age 1 month."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Carl June",
              "role": "Director, Center for Cellular Immunotherapies, UPenn",
              "mdrpediaSlug": "carl-june"
            }
          ],
          "sites": 80,
          "countries": ["USA", "Germany", "Japan", "UK", "France"]
        },
        {
          "id": "pluvicto-combo",
          "name": "Pluvicto + Checkpoint Inhibitor Combination",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Metastatic Castration-Resistant Prostate Cancer",
          "enrollment": 1200,
          "startDate": "2025-02",
          "estimatedCompletion": "2028-06",
          "description": "Radioligand therapy combined with pembrolizumab for enhanced tumor killing.",
          "primaryEndpoints": ["Overall survival", "Radiographic progression-free survival"],
          "latestUpdate": {
            "date": "2026-02-20",
            "summary": "Interim analysis triggered early. Results expected Q2 2026 with potential accelerated approval pathway."
          },
          "leadInvestigators": [],
          "sites": 200,
          "countries": ["USA", "Germany", "France", "Australia", "Canada"]
        },
        {
          "id": "iptacopan",
          "name": "Iptacopan (Factor B Inhibitor)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "rare-diseases",
          "indication": "C3 Glomerulopathy",
          "enrollment": 98,
          "startDate": "2024-03",
          "estimatedCompletion": "2026-09",
          "description": "Oral Factor B inhibitor for complement-mediated kidney disease.",
          "primaryEndpoints": ["Proteinuria reduction", "eGFR stabilization"],
          "latestUpdate": {
            "date": "2026-01-25",
            "summary": "66% of patients achieved >50% proteinuria reduction. BLA under FDA review with PDUFA date August 2026."
          },
          "leadInvestigators": [],
          "sites": 45,
          "countries": ["USA", "UK", "Germany", "Netherlands"]
        }
      ]
    },
    {
      "id": "regeneron",
      "name": "Regeneron",
      "logo": "https://logo.clearbit.com/regeneron.com",
      "headquarters": "Tarrytown, NY, USA",
      "founded": 1988,
      "focus": ["Immunology", "Oncology", "Ophthalmology", "Rare Diseases"],
      "marketCap": "$95.8B",
      "website": "https://www.regeneron.com",
      "trials": [
        {
          "id": "regn5458",
          "name": "REGN5458 (BCMAxCD3 Bispecific)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Relapsed/Refractory Multiple Myeloma",
          "enrollment": 500,
          "startDate": "2024-05",
          "estimatedCompletion": "2027-11",
          "description": "Bispecific antibody redirecting T-cells to BCMA-expressing myeloma cells.",
          "primaryEndpoints": ["Overall survival", "Complete response rate"],
          "latestUpdate": {
            "date": "2026-02-14",
            "summary": "Phase 2 showed 63% overall response rate. Registrational Phase 3 fully enrolled ahead of schedule."
          },
          "leadInvestigators": [],
          "sites": 85,
          "countries": ["USA", "France", "Spain", "Italy", "Japan"]
        },
        {
          "id": "regn-rsa",
          "name": "Pozelimab + Cemdisiran (C5 Inhibition)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "rare-diseases",
          "indication": "Generalized Myasthenia Gravis",
          "enrollment": 235,
          "startDate": "2024-08",
          "estimatedCompletion": "2026-12",
          "description": "Dual complement inhibition approach combining antibody and siRNA therapy.",
          "primaryEndpoints": ["MG-ADL score improvement", "Complete stable remission rate"],
          "latestUpdate": {
            "date": "2026-02-06",
            "summary": "Primary endpoint met with 4.2 point improvement vs placebo. Filing expected H2 2026."
          },
          "leadInvestigators": [],
          "sites": 75,
          "countries": ["USA", "Japan", "Germany", "Poland", "Canada"]
        }
      ]
    },
    {
      "id": "eli-lilly",
      "name": "Eli Lilly",
      "logo": "https://logo.clearbit.com/lilly.com",
      "headquarters": "Indianapolis, IN, USA",
      "founded": 1876,
      "focus": ["Neuroscience", "Oncology", "Diabetes", "Immunology"],
      "marketCap": "$685.2B",
      "website": "https://www.lilly.com",
      "trials": [
        {
          "id": "donanemab",
          "name": "Donanemab (TRAILBLAZER-ALZ 3)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "neurology",
          "indication": "Early Symptomatic Alzheimer's Disease",
          "enrollment": 3300,
          "startDate": "2023-10",
          "estimatedCompletion": "2027-06",
          "description": "Anti-amyloid antibody targeting N3pG amyloid for earlier-stage Alzheimer's patients.",
          "primaryEndpoints": ["iADRS score change", "Amyloid plaque clearance"],
          "latestUpdate": {
            "date": "2026-02-19",
            "summary": "FDA approved Kisunla (donanemab) in July 2025. Post-marketing study confirms 35% slowing of decline at 18 months."
          },
          "leadInvestigators": [
            {
              "name": "Dr. Reisa Sperling",
              "role": "Director, Center for Alzheimer Research, BWH",
              "mdrpediaSlug": null
            }
          ],
          "sites": 275,
          "countries": ["USA", "Japan", "UK", "Germany", "Australia"]
        },
        {
          "id": "orforglipron",
          "name": "Orforglipron (Oral GLP-1)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "metabolic",
          "indication": "Obesity and Type 2 Diabetes",
          "enrollment": 6000,
          "startDate": "2024-01",
          "estimatedCompletion": "2026-09",
          "description": "Once-daily oral GLP-1 receptor agonist for weight management and glycemic control.",
          "primaryEndpoints": ["Percent weight change", "HbA1c reduction"],
          "latestUpdate": {
            "date": "2026-02-11",
            "summary": "Phase 2 showed 14.7% weight loss at 36 weeks. Phase 3 on track for H2 2026 readout."
          },
          "leadInvestigators": [],
          "sites": 350,
          "countries": ["USA", "Mexico", "Japan", "Germany", "Australia"]
        },
        {
          "id": "lebrikizumab-ad",
          "name": "Lebrikizumab (IL-13 Inhibitor)",
          "phase": "Phase 4",
          "status": "Active",
          "category": "immunology",
          "indication": "Moderate-to-Severe Atopic Dermatitis",
          "enrollment": 800,
          "startDate": "2025-06",
          "estimatedCompletion": "2028-12",
          "description": "Real-world effectiveness study in diverse patient population.",
          "primaryEndpoints": ["IGA 0/1 response", "EASI-75 achievement"],
          "latestUpdate": {
            "date": "2026-01-20",
            "summary": "Approved in EU and US. Real-world data confirms efficacy with convenient monthly dosing."
          },
          "leadInvestigators": [],
          "sites": 150,
          "countries": ["USA", "Germany", "France", "UK", "Canada"]
        }
      ]
    },
    {
      "id": "gsk",
      "name": "GSK",
      "logo": "https://logo.clearbit.com/gsk.com",
      "headquarters": "London, UK",
      "founded": 2000,
      "focus": ["Vaccines", "Infectious Diseases", "Oncology", "Immunology"],
      "marketCap": "$78.5B",
      "website": "https://www.gsk.com",
      "trials": [
        {
          "id": "rsv-older-adults",
          "name": "Arexvy RSV Vaccine (Extended Protection Study)",
          "phase": "Phase 3b",
          "status": "Active",
          "category": "vaccines",
          "indication": "RSV Prevention in Older Adults",
          "enrollment": 12000,
          "startDate": "2024-09",
          "estimatedCompletion": "2027-03",
          "description": "Evaluating duration of protection and need for revaccination with approved RSV vaccine.",
          "primaryEndpoints": ["Efficacy against RSV-LRTD at Season 3", "Immunogenicity persistence"],
          "latestUpdate": {
            "date": "2026-02-16",
            "summary": "Season 2 efficacy of 67% against RSV-LRTD maintained. Single dose may provide multi-season protection."
          },
          "leadInvestigators": [],
          "sites": 200,
          "countries": ["USA", "UK", "Belgium", "Japan", "Australia"]
        },
        {
          "id": "blenrep-combo",
          "name": "Blenrep + Pomalidomide + Dexamethasone",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Relapsed/Refractory Multiple Myeloma",
          "enrollment": 430,
          "startDate": "2023-11",
          "estimatedCompletion": "2026-06",
          "description": "BCMA-targeted ADC in combination with standard of care for myeloma.",
          "primaryEndpoints": ["Progression-free survival", "Overall response rate"],
          "latestUpdate": {
            "date": "2026-02-03",
            "summary": "Primary analysis shows significant PFS improvement. Re-filing with FDA planned for Q2 2026."
          },
          "leadInvestigators": [],
          "sites": 140,
          "countries": ["USA", "Spain", "France", "Germany", "UK"]
        },
        {
          "id": "malaria-vaccine-r21",
          "name": "Malaria Vaccine Booster Study",
          "phase": "Phase 3",
          "status": "Active",
          "category": "vaccines",
          "indication": "Malaria Prevention in Children",
          "enrollment": 4500,
          "startDate": "2025-03",
          "estimatedCompletion": "2028-06",
          "description": "Evaluating optimal booster schedules for sustained malaria protection in endemic regions.",
          "primaryEndpoints": ["Clinical malaria incidence", "Antibody persistence"],
          "latestUpdate": {
            "date": "2026-01-28",
            "summary": "WHO prequalification received. Over 18 million doses shipped to endemic countries."
          },
          "leadInvestigators": [],
          "sites": 25,
          "countries": ["Ghana", "Kenya", "Burkina Faso", "Tanzania", "Nigeria"]
        }
      ]
    },
    {
      "id": "merck",
      "name": "Merck (MSD)",
      "logo": "https://logo.clearbit.com/merck.com",
      "headquarters": "Rahway, NJ, USA",
      "founded": 1891,
      "focus": ["Oncology", "Vaccines", "Infectious Disease", "Immunology"],
      "marketCap": "$245.8B",
      "website": "https://www.merck.com",
      "trials": [
        {
          "id": "keytruda-adjuvant",
          "name": "Keytruda Adjuvant Combinations",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "Multiple Solid Tumors (Adjuvant Setting)",
          "enrollment": 8500,
          "startDate": "2024-02",
          "estimatedCompletion": "2029-12",
          "description": "Master protocol evaluating pembrolizumab combinations across 12 tumor types in adjuvant setting.",
          "primaryEndpoints": ["Disease-free survival", "Overall survival"],
          "latestUpdate": {
            "date": "2026-02-17",
            "summary": "Positive results in renal cell carcinoma arm. Two additional tumor types showing promising interim data."
          },
          "leadInvestigators": [],
          "sites": 450,
          "countries": ["USA", "China", "Japan", "Germany", "UK", "Brazil"]
        },
        {
          "id": "v116-pneumonia",
          "name": "V116 (21-Valent Pneumococcal Vaccine)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "vaccines",
          "indication": "Pneumococcal Disease in Adults",
          "enrollment": 6400,
          "startDate": "2023-09",
          "estimatedCompletion": "2026-06",
          "description": "Next-generation pneumococcal vaccine covering 8 unique serotypes not in current vaccines.",
          "primaryEndpoints": ["Opsonophagocytic activity", "IgG geometric mean concentrations"],
          "latestUpdate": {
            "date": "2026-02-09",
            "summary": "Met all primary endpoints. BLA submitted to FDA; approval expected H2 2026."
          },
          "leadInvestigators": [],
          "sites": 180,
          "countries": ["USA", "Germany", "Japan", "Australia", "Belgium"]
        },
        {
          "id": "sotatercept",
          "name": "Sotatercept (PAH Treatment)",
          "phase": "Phase 3 (HYPERION)",
          "status": "Active",
          "category": "cardiovascular",
          "indication": "Pulmonary Arterial Hypertension",
          "enrollment": 600,
          "startDate": "2024-07",
          "estimatedCompletion": "2027-09",
          "description": "First-in-class activin signaling inhibitor as monotherapy for treatment-naive PAH.",
          "primaryEndpoints": ["6-minute walk distance", "Time to clinical worsening"],
          "latestUpdate": {
            "date": "2026-02-04",
            "summary": "FDA approved Winrevair (sotatercept) March 2024. HYPERION study exploring expanded use ongoing."
          },
          "leadInvestigators": [],
          "sites": 110,
          "countries": ["USA", "France", "Germany", "UK", "Italy"]
        }
      ]
    },
    {
      "id": "astrazeneca",
      "name": "AstraZeneca",
      "logo": "https://logo.clearbit.com/astrazeneca.com",
      "headquarters": "Cambridge, UK",
      "founded": 1999,
      "focus": ["Oncology", "Cardiovascular", "Respiratory", "Immunology"],
      "marketCap": "$198.4B",
      "website": "https://www.astrazeneca.com",
      "trials": [
        {
          "id": "dato-dxd",
          "name": "Dato-DXd (Trop2-directed ADC)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "HR+/HER2- Metastatic Breast Cancer",
          "enrollment": 930,
          "startDate": "2022-09",
          "estimatedCompletion": "2026-04",
          "description": "Antibody-drug conjugate targeting Trop2 with novel topoisomerase I inhibitor payload.",
          "primaryEndpoints": ["Progression-free survival", "Overall survival"],
          "latestUpdate": {
            "date": "2026-02-21",
            "summary": "Met primary PFS endpoint with 6.9 month improvement vs chemotherapy. FDA filing imminent."
          },
          "leadInvestigators": [],
          "sites": 175,
          "countries": ["USA", "Japan", "France", "Germany", "Spain"]
        },
        {
          "id": "nirsevimab-infants",
          "name": "Nirsevimab (Beyfortus) Effectiveness Study",
          "phase": "Phase 4",
          "status": "Active",
          "category": "infectious",
          "indication": "RSV Prevention in Infants",
          "enrollment": 25000,
          "startDate": "2025-07",
          "estimatedCompletion": "2027-06",
          "description": "Real-world effectiveness study of long-acting RSV monoclonal antibody in infants.",
          "primaryEndpoints": ["RSV hospitalization rate", "Medically attended RSV"],
          "latestUpdate": {
            "date": "2026-02-13",
            "summary": "First full RSV season data shows 83% reduction in hospitalizations vs historical controls."
          },
          "leadInvestigators": [],
          "sites": 500,
          "countries": ["USA", "France", "Spain", "UK", "Germany"]
        },
        {
          "id": "volrustomig",
          "name": "Volrustomig (PD-1/CTLA-4 Bispecific)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "oncology",
          "indication": "1L Metastatic NSCLC",
          "enrollment": 1100,
          "startDate": "2024-11",
          "estimatedCompletion": "2028-03",
          "description": "Novel bispecific antibody combining PD-1 and CTLA-4 blockade in single molecule.",
          "primaryEndpoints": ["Overall survival", "Progression-free survival"],
          "latestUpdate": {
            "date": "2026-01-22",
            "summary": "Phase 2 showed 48% ORR in PD-L1 high patients. Pivotal Phase 3 enrollment progressing well."
          },
          "leadInvestigators": [],
          "sites": 220,
          "countries": ["USA", "China", "Japan", "South Korea", "Germany"]
        }
      ]
    },
    {
      "id": "sanofi",
      "name": "Sanofi",
      "logo": "https://logo.clearbit.com/sanofi.com",
      "headquarters": "Paris, France",
      "founded": 2004,
      "focus": ["Immunology", "Oncology", "Vaccines", "Rare Diseases"],
      "marketCap": "$132.6B",
      "website": "https://www.sanofi.com",
      "trials": [
        {
          "id": "dupixent-copd",
          "name": "Dupixent in Type 2 COPD",
          "phase": "Phase 3",
          "status": "Active",
          "category": "respiratory",
          "indication": "COPD with Type 2 Inflammation",
          "enrollment": 1800,
          "startDate": "2023-05",
          "estimatedCompletion": "2026-03",
          "description": "IL-4/IL-13 blockade for COPD patients with eosinophilic phenotype.",
          "primaryEndpoints": ["Annualized rate of moderate/severe exacerbations", "FEV1 change"],
          "latestUpdate": {
            "date": "2026-02-22",
            "summary": "Primary endpoint met with 30% reduction in exacerbations. First biologic therapy for COPD potentially launching 2026."
          },
          "leadInvestigators": [],
          "sites": 280,
          "countries": ["USA", "Germany", "France", "UK", "Japan", "China"]
        },
        {
          "id": "itepekimab",
          "name": "Itepekimab (Anti-IL-33)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "respiratory",
          "indication": "Moderate-to-Severe Asthma",
          "enrollment": 2200,
          "startDate": "2024-04",
          "estimatedCompletion": "2027-06",
          "description": "Monoclonal antibody targeting IL-33, a key upstream cytokine in allergic inflammation.",
          "primaryEndpoints": ["Severe exacerbation rate", "Pre-bronchodilator FEV1"],
          "latestUpdate": {
            "date": "2026-01-18",
            "summary": "Phase 2b showed benefit across all asthma phenotypes including those not responsive to existing biologics."
          },
          "leadInvestigators": [],
          "sites": 190,
          "countries": ["USA", "France", "Germany", "Japan", "Poland"]
        },
        {
          "id": "rilzabrutinib",
          "name": "Rilzabrutinib (BTK Inhibitor)",
          "phase": "Phase 3",
          "status": "Active",
          "category": "rare-diseases",
          "indication": "Immune Thrombocytopenia (ITP)",
          "enrollment": 300,
          "startDate": "2024-09",
          "estimatedCompletion": "2026-12",
          "description": "Oral reversible BTK inhibitor for chronic ITP patients.",
          "primaryEndpoints": ["Durable platelet response", "Reduction in bleeding events"],
          "latestUpdate": {
            "date": "2026-02-07",
            "summary": "Phase 2 showed 50% durable response rate. Potential first oral therapy for ITP."
          },
          "leadInvestigators": [],
          "sites": 85,
          "countries": ["USA", "France", "Germany", "UK", "Canada"]
        }
      ]
    }
  ]
}
